Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
A Metropolitan Transportation Authority rendering shows a conceptual interior of a future Second Avenue Subway station in Harlem, illustrating platform circulation, train clearances and passenger flow ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A novel GLP-1 and amylin receptor agonist reduced HbA1c ...
Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...
Equinor ASA, Shell PLC and TotalEnergies SE have approved the second phase of the Northern Lights carbon, capture and storage (CCS) project in Norway with a NOK 7.5 billion ($700 million) investment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results